See Supplemental Patient Information
- Not intended for intravenous or intramuscular administration
- It should not be mixed with other insulin preparations
- Periodic monitoring of blood sugar levels is recommended for all patients with diabetes
- A change in insulin dose may be required when changing from one insulin product to another or while changing the insulin strength. Any changes in insulin dose should be made cautiously under medical supervision
- So that any one site is not injected more than once every 1-2 wks, a planned rotation of sites within an area should be followed
- Hypoglycemia is the most common adverse reaction of insulin therapy. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary/permanent impairment of brain function or even death. It may result from excessive insulin dose, missed or reduced meal, or increased work or exercise without eating. Do not use in patients with pre-existing hypoglycemia
- Exercise caution in patients with hypoglycemia unawareness and in those who may be predisposed to hypoglycemia
- The prescription for NovoLog Mix 70/30 should be clearly written in order to avoid confusion with other insulin products such as NovoLog or Novolin 70/30
- Product should appear uniformly white and cloudy; do not use if it looks clear or if it contains solid particles
- Therapy may lead to hypokalemia that may cause respiratory paralysis, ventricular arrhythmia, and death, if left untreated
- Severe, life-threatening allergic reactions, including anaphylaxis, may occur with insulin products
- Concomitant use of thiazolidinediones can cause dose-related fluid retention, which may lead to or exacerbate heart failure. Monitor for signs and symptoms of heart failure and treat accordingly or consider discontinuation or dose reduction
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Hypoglycemia
- Changes in doses of other hypoglycemic medications
- Infection
- Emotional or physiologic stress
- Illness
- Hypokalemia
- Changes in diet and exercise
Supplemental Patient Information
- Provide continued education and advice on regular glucose monitoring, insulin therapies, injection technique, periodic glycosylated hemoglobin testing, recognition and management of hypo- and hyperglycemia, adherence to diet planning, timing of dose, complications of insulin therapy, life-style management, and proper storage of insulin
- Inform patients that frequent, patient-performed blood glucose measurements are critical to achieve optimal glycemic control and avoid both hypo- and hyperglycemia and diabetic ketoacidosis
- Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to exercise caution when driving or operating machinery
- Instruct patients to carefully verify if they are administering the appropriate insulin to avoid medication errors between insulin aspart protamine/insulin aspart and any other insulin
- Advise patients to rotate subcutaneous injection sites and keep a record of sites used, to help prevent fatty tissue breakdown
Pregnancy Category:C
Breastfeeding: Safety unknown. There are no adequate and well-controlled studies of the use of insulin aspart protamine/insulin aspart in lactating women. Women with diabetes who are breastfeeding may require adjustments of their insulin doses.
Pricing data from www.DrugStore.com in U.S.A.
- NovoLOG Mix 70/30 70-30 % SUSP [Vial] (NOVO NORDISK)
10 % = $137.55
30 % = $384.27
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
